Merck & Co., Inc. $MRK Shares Sold by Investment Management Corp of Ontario

by · The Markets Daily

Investment Management Corp of Ontario lessened its stake in Merck & Co., Inc. (NYSE:MRK – Free Report) by 4.3% in the 4th quarter, Holdings Channel reports. The firm owned 290,226 shares of the company’s stock after selling 12,927 shares during the period. Investment Management Corp of Ontario’s holdings in Merck & Co., Inc. were worth $30,549,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in MRK. D.A. Davidson & CO. lifted its position in shares of Merck & Co., Inc. by 4.4% during the 4th quarter. D.A. Davidson & CO. now owns 576,959 shares of the company’s stock worth $60,731,000 after purchasing an additional 24,576 shares during the last quarter. Farther Finance Advisors LLC lifted its position in shares of Merck & Co., Inc. by 48.9% during the 4th quarter. Farther Finance Advisors LLC now owns 97,818 shares of the company’s stock worth $10,296,000 after purchasing an additional 32,114 shares during the last quarter. Coldstream Capital Management Inc. lifted its position in shares of Merck & Co., Inc. by 12.7% during the 3rd quarter. Coldstream Capital Management Inc. now owns 123,366 shares of the company’s stock worth $10,364,000 after purchasing an additional 13,940 shares during the last quarter. Campbell Capital Management Inc. purchased a new stake in shares of Merck & Co., Inc. during the 3rd quarter worth $1,866,000. Finally, Norris Perne & French LLP MI lifted its position in shares of Merck & Co., Inc. by 12.8% during the 4th quarter. Norris Perne & French LLP MI now owns 252,162 shares of the company’s stock worth $26,543,000 after purchasing an additional 28,635 shares during the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Merck & Co., Inc. Price Performance

Shares of NYSE:MRK opened at $115.67 on Thursday. The company’s fifty day moving average price is $116.22 and its 200 day moving average price is $113.53. Merck & Co., Inc. has a 12 month low of $76.66 and a 12 month high of $125.14. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. The firm has a market capitalization of $285.69 billion, a P/E ratio of 32.58, a P/E/G ratio of 2.59 and a beta of 0.21.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, topping the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The firm had revenue of $16.29 billion for the quarter, compared to analyst estimates of $15.85 billion. During the same period last year, the business earned $2.22 EPS. Merck & Co., Inc.’s revenue for the quarter was up 4.9% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. As a group, sell-side analysts predict that Merck & Co., Inc. will post 5.17 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, July 8th. Investors of record on Monday, June 15th will be paid a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a yield of 2.9%. The ex-dividend date is Monday, June 15th. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 95.77%.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on MRK shares. Weiss Ratings cut shares of Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a research report on Friday, May 15th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $142.00 price objective on shares of Merck & Co., Inc. in a research report on Monday, March 30th. Citigroup started coverage on shares of Merck & Co., Inc. in a research report on Wednesday, May 6th. They set a “neutral” rating and a $125.00 price objective for the company. Zacks Research raised shares of Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 17th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Merck & Co., Inc. from $125.00 to $135.00 and gave the stock an “overweight” rating in a research report on Monday, April 6th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and seven have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $128.18.

View Our Latest Research Report on Merck & Co., Inc.

About Merck & Co., Inc.

(Free Report)

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

See Also

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).